Kineta, Inc. (KA)

NASDAQ: KA · IEX Real-Time Price · USD
0.452
-0.028 (-5.83%)
At close: May 17, 2024, 4:00 PM
0.450
-0.002 (-0.44%)
After-hours: May 17, 2024, 7:48 PM EDT
-5.83%
Market Cap 5.34M
Revenue (ttm) 5.16M
Net Income (ttm) -17.89M
Shares Out 11.35M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 36,956
Open 0.480
Previous Close 0.480
Day's Range 0.442 - 0.490
52-Week Range 0.334 - 5.390
Beta n/a
Analysts Strong Buy
Price Target 8.00 (+1,669.91%)
Earnings Date May 15, 2024

About KA

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with ad... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 11
Stock Exchange NASDAQ
Ticker Symbol KA
Full Company Profile

Financial Performance

In 2023, Kineta's revenue was $5.44 million, an increase of 178.65% compared to the previous year's $1.95 million. Losses were -$14.10 million, -77.76% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for KA stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target
$8.0
(1,669.91% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

3 days ago - GlobeNewsWire

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

5 weeks ago - GlobeNewsWire

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial

2 months ago - GlobeNewsWire

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts No dose limiting toxicities observed at any dose level Cleared fifth of s...

2 months ago - GlobeNewsWire

Kineta Announces Restructuring and Exploration of Strategic Alternatives

SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

2 months ago - GlobeNewsWire

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

3 months ago - GlobeNewsWire

Kineta to Present at Upcoming Investor Conferences

SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

3 months ago - GlobeNewsWire

Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

3 months ago - GlobeNewsWire

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inflammatory...

4 months ago - GlobeNewsWire

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

SEATTLE, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

4 months ago - GlobeNewsWire

Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer

VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse Events

5 months ago - GlobeNewsWire

Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023

SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

6 months ago - GlobeNewsWire

Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

6 months ago - GlobeNewsWire

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines Achieved Greater Than Dose-Proportional Pharmacokinetics Biomarker Results Demonstrate Robust V...

6 months ago - GlobeNewsWire

Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in combination with pembrolizumab in patients with advanc...

7 months ago - GlobeNewsWire

Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and Specificity Drives Strong T Cell Activation and Proliferation as well as NK Cell Activation Demonstrated In Vivo Antitumor Efficacy ...

7 months ago - GlobeNewsWire

Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

The Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic Data of KVA12123 in the Monotherapy Arm (Part A)

7 months ago - GlobeNewsWire

Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023

SEATTLE, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

7 months ago - GlobeNewsWire

Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023

SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...

7 months ago - GlobeNewsWire

Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology...

8 months ago - GlobeNewsWire

Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

Preclinical data highlights CD27's mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors Preclinical data highlights CD27's mechanism ...

8 months ago - GlobeNewsWire

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology...

8 months ago - GlobeNewsWire

Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level

8 months ago - GlobeNewsWire

Kineta Announces Participation at October Investor Conferences

SEATTLE, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune...

8 months ago - GlobeNewsWire

Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

SEATTLE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune...

8 months ago - GlobeNewsWire